Go to deals
Consumer & Retail | Healthcare

Merck Animal Health has acquired a controlling stake in Vallée S.A.

Merck Animal Health has acquired a controlling stake in Vallée S.A.

Merck Animal Health, known as MSD outside the USA and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets.

Vallée was founded in 1961 in Uberlândia, State of Minas Gerais, as a company dedicated to the production of vaccines for foot-and-mouth disease. Vallée is one of the largest animal health companies in Brazil, with a diversified product offering, including vaccines, antiparasiticides, supplements, therapeutic, reproduction and nutritional products for both production animals and pets.

One of Oaklins’ teams in Brazil acted as the sole financial advisor for Merck Animal Health in this transaction.

Parties

Talk to the deal team

Richard Rainer

Managing Partner
São Paulo, Brazil
Oaklins Olimpia Partners

Victor Andreoli

Partner
São Paulo, Brazil
Oaklins Olimpia Partners

Irajá Guimarães

Partner
São Paulo, Brazil
Oaklins Olimpia Partners

Related deals

The Providence Projects has been acquired by UKAT Group
Private Equity | Healthcare

The Providence Projects has been acquired by UKAT Group

Celebrity-success rehabilitation center, The Providence Projects, has joined The UK Addiction Treatment (UKAT) Group, backed by Sullivan Street Equity Partners.

Learn more
St. Claraspital AG has been acquired by University Hospital Basel
Healthcare

St. Claraspital AG has been acquired by University Hospital Basel

University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care. The completion of the transaction is subject to clearance by the Swiss Competition Commission (COMCO).

Learn more
A share exchange agreement for making NARUMIYA a wholly owned subsidiary of World has been executed
Consumer & Retail

A share exchange agreement for making NARUMIYA a wholly owned subsidiary of World has been executed

World Co., Ltd. and NARUMIYA INTERNATIONAL Co., Ltd. have entered into a definitive share exchange agreement, under which World will acquire all outstanding shares of NARUMIYA and make it a wholly owned subsidiary. The share exchange is scheduled to take effect on 1 October 2025. Under the terms of the agreement, NARUMIYA shareholders will receive 0.58 shares of World stock for each Narumiya share they hold.

Learn more